Eylea

Kodiak's stock doubles with win for resurrected eye disease drug

Two of Kodiak's candidates matched aflibercept in a phase 3 trial, positioning the biotech to seek approval of one of the eye disease assets this year.

Nick Paul Taylor Sep 28, 2026 8:37am

Unity's stock tumbles after eye treatment fails to match Eylea

Mar 24, 2025 11:11am

Opthea's eye disease drug defeated by Eylea in phase 3

Mar 24, 2025 5:24am

graphic of a larger shark chomping up a smaller one

Regeneron snaps up eye biotech, snaring science but not staff

Jan 2, 2025 3:58pm

Innovent's anti-VEGF drug matches Eylea in eye disease trial

Mar 19, 2024 10:36am

Images of two chess pieces right in front of each other

Unity preps for Eylea battle following extended midstage test

Apr 24, 2023 10:25am